1,089
Participants
Start Date
November 30, 2012
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2014
Matching Placebo
Low Dose GRT6005
Medium Dose GRT6005
High Dose GRT6005
Tapentadol
HU011, Budapest
AT004, Vienna
BE001, Brussels
HU015, Budapest
AT001, Vienna
AT005, Vienna
AT006, Vienna
HU005, Budapest
DK001, Frederiksberg
Site DK002, Glostrup Municipality
BE002, Edegem
AT003, Senftenberg
BE004, Genk
HU014, Nyíregyháza
DK003, Odense
HU003, Kecskemét
HU002, Kiskunfélegyháza
HU010, Baja
HU001, Makó
HU004, Szekszárd
ES006, Barcelona
HU012, Budapest
HU009, Nagykanizsa
DK004, Aalborg
DE014, Berlin
SE002, Stockholm
DE018, Berlin
ES004, A Coruña
FI003, Lahti
ES005, Santiago de Compostela
DE001, Hamburg
DE006, Hamburg
ES001, Madrid
ES013, Madrid
ES008, Málaga
DE008, Hanover
ES003, Oviedo
ES011, Oviedo
ES007, Seville
DE011, Bochum
DE016, Essen
SE001, Skene
DE005, Bad Nauheim
DE013, Rodgau
DE017, Wiesbaden
FI005, Kokkola
FI001, Kuopio
DE009, Mosbach
DE004, Munich
DE015, Böhlen
DE007, Dresden
DE002, Leipzig
DE019, Leipzig
HU008, Békéscsaba
SE004, Vällingby
NL003, Almere Stad
NL002, Eindhoven
NL005, Tiel
PL002, Elblag
PL015, Gdynia
PL006, Gdynia
PL001, Katowice
PL014, Katowice
PL008, Krakow
PL013, Krakow
PL011, Krakow
PL009, Lublin
PL016, Poznan
PL018, Poznan
PL012, Warsaw
PL004, Warsaw
PL010, Wroclaw
PL017, Wroclaw
PL005, Zgierz
ES002, Barcelona
GB002, Liverpool
GB005, London
GB003, Manchester
GB004, Plymouth
Collaborators (1)
Forest Laboratories
INDUSTRY
Tris Pharma, Inc.
INDUSTRY